Srishty Agarwal
Research Subjects
Srishty Agarwal has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Rohit Jain
Penn State Milton S. Hershey Medical Center
2 shared publications - Amteshwar Singh
Johns Hopkins University School of Medicine
1 shared publication Angela Jones
Department of Microbiology, Mayo Clinic Florida, Jacksonville, USA, FL
1 shared publication- Baltej Singh
Department of Medicine, Christiana Care Union Hospital, Elkton, MD, USA
1 shared publication - Jerome Gnanaraj
Johns Hopkins University School of Medicine
1 shared publication Justin M. Oring
Department of Infectious Diseases, Mayo Clinic Florida, Jacksonville, USA, FL
1 shared publication
Latest Publications
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 315-323
Hospital teaching status and COVID-19 outcomes: a multicenter retrospective cohort study in the emergency department
Differences in COVID-19 outcomes may reflect variation in clinical expertise, institutional resources, and care coordination between academic teaching and non-teaching hospitals. We evaluated differences in patient characteristics, resource utilization, and mortality between hospital types during the early phase of the pandemic. We conducted a retrospective cohort study of 2,767 adults (≥18 years) with COVID-19 presenting to five hospitals within the Johns Hopkins Health System between March 1 and 4 May 2020. Patient characteristics, clinical presentation, laboratory findings, and outcomes were compared between academic teaching and non-teaching hospitals. Group comparisons were performed using unpaired t-tests and chi-square tests. Multivariable logistic regression assessed the association between hospital teaching status and in-hospital mortality. A primary model included variables with minimal missing values, while a secondary model incorporated laboratory variables using complete-case analysis. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow goodness-of-fit test. Of 2,767 patients, 801 (29%) were evaluated at academic teaching hospitals. Patients at academic centers had higher comorbidity burden and more severe clinical presentation, whereas patients at non-teaching hospitals had lower access to healthcare resources. Emergency department length of stay (430 vs 269 minutes, p < 0.001), hospital length of stay (12.2 vs 4.4 days), and hospitalization costs ($55,868 vs $5,543, p < 0.001) were higher in teaching hospitals. Mortality was higher in non-teaching hospitals across both adjusted models. In the primary (n = 2,605) model (OR 6.86; 95% CI 5.18-9.10; AUC 0.70) and the secondary (n = 372) model (OR 13.4; 95% CI 7.28-24.7; AUC 0.82). These findings suggest that structural differences, including resource availability and healthcare access, may contribute to disparities in COVID-19 outcomes. Non-teaching hospitals, while managing high volumes with limited resources, had markedly higher mortality despite lower comorbidity burden. Further investigation of system-level determinants of outcomes during public health emergencies is warranted.
- 3 April 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (3) , 315-323
Hospital teaching status and COVID-19 outcomes: a multicenter retrospective cohort study in the emergency department
Differences in COVID-19 outcomes may reflect variation in clinical expertise, institutional resources, and care coordination between academic teaching and non-teaching hospitals. We evaluated differences in patient characteristics, resource utilization, and mortality between hospital types during the early phase of the pandemic. We conducted a retrospective cohort study of 2,767 adults (≥18 years) with COVID-19 presenting to five hospitals within the Johns Hopkins Health System between March 1 and 4 May 2020. Patient characteristics, clinical presentation, laboratory findings, and outcomes were compared between academic teaching and non-teaching hospitals. Group comparisons were performed using unpaired t-tests and chi-square tests. Multivariable logistic regression assessed the association between hospital teaching status and in-hospital mortality. A primary model included variables with minimal missing values, while a secondary model incorporated laboratory variables using complete-case analysis. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow goodness-of-fit test. Of 2,767 patients, 801 (29%) were evaluated at academic teaching hospitals. Patients at academic centers had higher comorbidity burden and more severe clinical presentation, whereas patients at non-teaching hospitals had lower access to healthcare resources. Emergency department length of stay (430 vs 269 minutes, p < 0.001), hospital length of stay (12.2 vs 4.4 days), and hospitalization costs ($55,868 vs $5,543, p < 0.001) were higher in teaching hospitals. Mortality was higher in non-teaching hospitals across both adjusted models. In the primary (n = 2,605) model (OR 6.86; 95% CI 5.18-9.10; AUC 0.70) and the secondary (n = 372) model (OR 13.4; 95% CI 7.28-24.7; AUC 0.82). These findings suggest that structural differences, including resource availability and healthcare access, may contribute to disparities in COVID-19 outcomes. Non-teaching hospitals, while managing high volumes with limited resources, had markedly higher mortality despite lower comorbidity burden. Further investigation of system-level determinants of outcomes during public health emergencies is warranted.
- Open Access
- 10 March 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 43-46
Balancing Ethics, Education, and Compassion in Physician-Assisted Suicide and Euthanasia
Objective: It is 2024, and the debate of physician-assisted suicide and euthanasia remains highly complex and impactful. This discussion extends to the legal and ethical theories that affect these issues, but also profoundly impact real lives and families. Understanding where we stand today requires a look back at historical contexts and current perspectives, while pointing out the necessity of raising awareness concerning educating healthcare professionals and the role of palliative care. Methods: A review of historical developments, legal cases, and current perspectives related to physician assisted suicide and euthanasia was conducted to understand how these practices have evolved and how they influence modern medical decision-making and ethical discussions. Results: A major turning point occurred in the 1980s when Jack Kevorkian’s assisted suicide device was made, raising concerns in courts, including the Supreme Court cases of Vacco v. Quill (1997) and Washington v. Glucksberg (1997), which ultimately ruled that the legality of physician-assisted suicide should be determined by individual states. Oregon’s 1999 “Death with Dignity” law set the standard and became evident in other states with similar legislation, showing a growing trend of acceptance of physician- assisted suicide in the US, while euthanasia remains legalized only in a few countries abroad. Conclusion: The current issue remains the debate between individual autonomy and fears of ethical misuse, along with possible consequences for palliative care. Providing thorough training to healthcare providers and ensuring that patients and families receive clear information about their choices must be a priority. A common approach to physician-assisted suicide may help standardize care and address ethical and practical challenges while emphasizing respect and compassion in end-of-life decisions.
- 10 March 2026
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 8, 43-46
Open AccessBalancing Ethics, Education, and Compassion in Physician-Assisted Suicide and Euthanasia
Objective: It is 2024, and the debate of physician-assisted suicide and euthanasia remains highly complex and impactful. This discussion extends to the legal and ethical theories that affect these issues, but also profoundly impact real lives and families. Understanding where we stand today requires a look back at historical contexts and current perspectives, while pointing out the necessity of raising awareness concerning educating healthcare professionals and the role of palliative care. Methods: A review of historical developments, legal cases, and current perspectives related to physician assisted suicide and euthanasia was conducted to understand how these practices have evolved and how they influence modern medical decision-making and ethical discussions. Results: A major turning point occurred in the 1980s when Jack Kevorkian’s assisted suicide device was made, raising concerns in courts, including the Supreme Court cases of Vacco v. Quill (1997) and Washington v. Glucksberg (1997), which ultimately ruled that the legality of physician-assisted suicide should be determined by individual states. Oregon’s 1999 “Death with Dignity” law set the standard and became evident in other states with similar legislation, showing a growing trend of acceptance of physician- assisted suicide in the US, while euthanasia remains legalized only in a few countries abroad. Conclusion: The current issue remains the debate between individual autonomy and fears of ethical misuse, along with possible consequences for palliative care. Providing thorough training to healthcare providers and ensuring that patients and families receive clear information about their choices must be a priority. A common approach to physician-assisted suicide may help standardize care and address ethical and practical challenges while emphasizing respect and compassion in end-of-life decisions.
- Open Access
- 29 August 2025
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 19 (1)
Obstructive Sleep Apnea in Pregnancy and its Impact on Maternal-Fetal Health: A Hidden Threat - Narrative Review
Obstructive sleep apnea (OSA), characterised by apnea or hypopnea, often presents with symptoms such as gasping or snoring. However, these symptoms can be nonspecific and are frequently overlooked, particularly in pregnant women, where they are often attributed to normal physiological adaptations, leading to underdiagnosis and negative maternal and fetal outcomes. This narrative review examines the implications of OSA during pregnancy, highlighting the importance of early screening and evaluating available treatment options. We reviewed various articles on PubMed and Google Scholar about the impact of OSA during pregnancy, screening methodologies, and treatment effectiveness. OSA often increases sympathetic activity along with immune dysfunction, resulting in adverse outcomes like gestational hypertension, preeclampsia, gestational diabetes, cardiomyopathy, depression, and higher rates of cesarean deliveries, while the fetus suffers from intrauterine growth restriction (IUGR), preterm births, and perinatal mortality. Various screening tools, such as the Berlin Questionnaire, Epworth Sleepiness Scale (ESS), STOP-BANG, and Wisconsin questionnaires, aid in early diagnosis. Treatment options include lifestyle modifications, positive airway pressure (PAP) therapy, either continuous (CPAP) or bilevel (BiPAP), hypoglossal nerve stimulation (HGNS), mandibular advancement devices (MAD), and maxillomandibular advancement (MMA) surgery, with CPAP being identified as the preferred treatment. To reduce adverse outcomes for both the mother and the fetus, early detection and treatment of OSA in pregnant women are essential. Increased awareness among expectant mothers, routine screening using validated questionnaires, and appropriate treatment selection can not only decrease fetal complications but also reduce the risk of long-term adverse effects of OSA on maternal health.
- 29 August 2025
- Published by Bentham Science Publishers Ltd. in The Open Respiratory Medicine Journal
- Vol. 19 (1)
Open AccessObstructive Sleep Apnea in Pregnancy and its Impact on Maternal-Fetal Health: A Hidden Threat - Narrative Review
Obstructive sleep apnea (OSA), characterised by apnea or hypopnea, often presents with symptoms such as gasping or snoring. However, these symptoms can be nonspecific and are frequently overlooked, particularly in pregnant women, where they are often attributed to normal physiological adaptations, leading to underdiagnosis and negative maternal and fetal outcomes. This narrative review examines the implications of OSA during pregnancy, highlighting the importance of early screening and evaluating available treatment options. We reviewed various articles on PubMed and Google Scholar about the impact of OSA during pregnancy, screening methodologies, and treatment effectiveness. OSA often increases sympathetic activity along with immune dysfunction, resulting in adverse outcomes like gestational hypertension, preeclampsia, gestational diabetes, cardiomyopathy, depression, and higher rates of cesarean deliveries, while the fetus suffers from intrauterine growth restriction (IUGR), preterm births, and perinatal mortality. Various screening tools, such as the Berlin Questionnaire, Epworth Sleepiness Scale (ESS), STOP-BANG, and Wisconsin questionnaires, aid in early diagnosis. Treatment options include lifestyle modifications, positive airway pressure (PAP) therapy, either continuous (CPAP) or bilevel (BiPAP), hypoglossal nerve stimulation (HGNS), mandibular advancement devices (MAD), and maxillomandibular advancement (MMA) surgery, with CPAP being identified as the preferred treatment. To reduce adverse outcomes for both the mother and the fetus, early detection and treatment of OSA in pregnant women are essential. Increased awareness among expectant mothers, routine screening using validated questionnaires, and appropriate treatment selection can not only decrease fetal complications but also reduce the risk of long-term adverse effects of OSA on maternal health.
- Open Access
- 19 May 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e946589
Low Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports
BACKGROUND Cryptococcus is a yeast-like fungus commonly found in soil and typically causes disease in immunocompromised individuals due to impaired cell-mediated immunity. While the central nervous system (CNS) and lungs are most frequently affected, disseminated disease can involve multiple organs, including the skin, liver, spleen, kidneys, and bone marrow. Symptoms such as headache, fever, and altered mental status often require extensive diagnostic evaluation. CASE REPORT We present 2 unusual cases of cryptococcal growth in the blood without meningoencephalitis, with low cryptococcal antigen titres (1: 80 in both cases). The first case involves a post-kidney transplant patient with respiratory symptoms who underwent bronchoalveolar lavage (BAL), revealing Cryptococcus growth. A subsequent positive blood culture confirmed disseminated cryptococcosis, and the patient was treated with antifungal therapy. The second case is of a patient with HIV, non-adherent to treatment, who developed a complicated infection course. The cryptococcal antigen was positive in the serum, prompting treatment with a high-dose antifungal regimen. Despite negative results in BAL and cerebrospinal fluid, the blood culture was positive for Cryptococcus, necessitating intensive antifungal therapy according to protocolized guidelines. CONCLUSIONS These cases highlight the unusual presentation of disseminated cryptococcal infection with low serum antigen titres (1: 80) and positive blood culture, indicating disseminated infection even without CNS involvement. This emphasizes the importance of considering disseminated cryptococcosis in the differential diagnosis of immunocompromised patients, even with low antigen titres in serum. It suggests that clinicians should order blood cultures to alter management strategies, particularly in patients with atypical presentations.
- 19 May 2025
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 26, e946589
Open AccessLow Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports
BACKGROUND Cryptococcus is a yeast-like fungus commonly found in soil and typically causes disease in immunocompromised individuals due to impaired cell-mediated immunity. While the central nervous system (CNS) and lungs are most frequently affected, disseminated disease can involve multiple organs, including the skin, liver, spleen, kidneys, and bone marrow. Symptoms such as headache, fever, and altered mental status often require extensive diagnostic evaluation. CASE REPORT We present 2 unusual cases of cryptococcal growth in the blood without meningoencephalitis, with low cryptococcal antigen titres (1: 80 in both cases). The first case involves a post-kidney transplant patient with respiratory symptoms who underwent bronchoalveolar lavage (BAL), revealing Cryptococcus growth. A subsequent positive blood culture confirmed disseminated cryptococcosis, and the patient was treated with antifungal therapy. The second case is of a patient with HIV, non-adherent to treatment, who developed a complicated infection course. The cryptococcal antigen was positive in the serum, prompting treatment with a high-dose antifungal regimen. Despite negative results in BAL and cerebrospinal fluid, the blood culture was positive for Cryptococcus, necessitating intensive antifungal therapy according to protocolized guidelines. CONCLUSIONS These cases highlight the unusual presentation of disseminated cryptococcal infection with low serum antigen titres (1: 80) and positive blood culture, indicating disseminated infection even without CNS involvement. This emphasizes the importance of considering disseminated cryptococcosis in the differential diagnosis of immunocompromised patients, even with low antigen titres in serum. It suggests that clinicians should order blood cultures to alter management strategies, particularly in patients with atypical presentations.